AbbVie broadens immunology focus with $10.9 billion Apogee deal

Seeking to replace blockbuster drugs that will soon lose patent protection, drug-maker AbbVie purchased a biotech firm for nearly $11 billion for its pipeline of drugs to treat inflammatory disease.